- Investigator
- Carl J Pepine
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Coronary Disease , 195 publications
- Myocardial Ischemia , 181 publications
- Coronary Artery Disease , 147 publications
- Hypertension , 141 publications
Research activity
Focus
My career has focused on improving our understanding of mechanisms underlying ischemic heart disease (IHD) and related adverse outcomes. I have conducted extensive investigations in coronary artery disease (CAD), hypertension, treatment resistant hypertension, vascular biology, and therapeutic applications related to vascular dysfunction. My work has centered on how IHD becomes manifest with and without large coronary artery obstructive disease (CAD). Much of this work is concentrated in women with known or suspect IHD. A major goal of clinical research is development of actionable information of sufficient power to alter medical care and improve patient health by information obtained through performance of clinical trials. To this end, I conceived and led the first randomized controlled international mega-trial of blood pressure control for patients with CAD (INVEST). My experience also includes being a principal investigator (PI) in multiple NHLBI-funded projects [Women’s Ischemia Syndrome Evaluation (WISE), WISE-CVD, WISE HFpEF, MayWEST, Asymptomatic Cardiac Ischemia Pilot (ACIP), Psychophysiologic Interventions of Myocardial Ischemia (PIMI), Bypass Angioplasty Revascularization Investigation 2-Diabetes Trial (BARI2D), etc.] and many other industry-sponsored studies. More recently I have been working in cardiovascular recovery and regeneration with cell based therapies as a PI in the NHLBI Cardiovascular Cell Therapy Network (CCTRN)- 1 and 2, as well as studies funded by the the cell and gene biomedical industry.
Active clinical trials
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE * cardiovascular (CV) death, myocardial infarction…
- Investigator
- Carl J Pepine
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of…
- Investigator
- Carl J Pepine
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
1040 publications
2024
Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial
Circulation: Cardiovascular Interventions
Publisher's site2024
Arterial stiffness assessment in coronary microvascular dysfunction and heart failure with preserved ejection fraction: An initial report from the WISE-CVD continuation study.
American heart journal plus : cardiology research and practice
PubMed • Publisher's site2024
Comparison of risk profiles of participants in the Women's IschemiA TRial to reduce events in non-ObstRuctive CAD (WARRIOR) trial, using coronary computed tomography angiography vs invasive coronary angiography.
Progress in cardiovascular diseases
PubMed • Publisher's site2024
Elevated high-density lipoprotein cholesterol and adverse outcomes in women with symptoms of ischemic heart disease.
American heart journal plus : cardiology research and practice
PubMed • Publisher's site2024
Initial Antihypertensive Prescribing in Relation to Blood Pressure Among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium
Hypertension
Publisher's site